- Halozyme has increased its full-year 2025 revenue forecast to a range of $1.28 billion to $1.36 billion, up from the previous guidance of $1.20 billion to $1.28 billion. The market estimate was $1.25 billion.
- The company now expects adjusted Earnings Per Share (EPS) for 2025 to be between $6.00 and $6.40, compared to the earlier forecast of $5.30 to $5.70. The market estimate was $5.32.
- Halozyme anticipates its adjusted EBITDA for 2025 to be between $865 million and $915 million, up from the prior forecast of $790 million to $840 million.
- For the second quarter, Halozyme reported an EPS of $1.33, exceeding the estimate of $280.3 million with an actual revenue of $325.7 million.
- The company’s adjusted EPS for the second quarter was $1.54, surpassing the market estimate of $1.25.
- Research and Development (R&D) expenses amounted to $17.5 million, slightly above the estimate of $16.6 million.
- Cash and cash equivalents were reported at $61.9 million, significantly below the estimate of $442.2 million.
- Operating income for the second quarter was $202.4 million, higher than the estimated $159.8 million.
- Halozyme is raising its financial guidance for 2025 and expects year-over-year growth of 26% to 33% in total revenue, 37% to 45% in adjusted EBITDA, and 42% to 51% in non-GAAP diluted EPS.
- Dr. Helen Torley, President and CEO of Halozyme, commented on the strong performance and growth trends, signifying an upward revision in the financial guidance for the second time this year.
- Analyst recommendations include 5 buys, 4 holds, and 1 sell.
Halozyme Therapeutics on Smartkarma
Analyst coverage of Halozyme Therapeutics on Smartkarma by Baptista Research indicates a positive outlook for the company’s future. In their report titled “Halozyme Therapeutics Unlocks Billion-Dollar Royalty Streams with Next-Gen Drug Formulations; How Will It Shape The Future Top-Line?”, the analysts highlight the company’s mixed first quarter 2025 performance, showcasing notable strengths and some challenges. Halozyme reported a 35% year-over-year increase in total revenue to $265 million, driven by a 39% rise in royalty revenue, particularly from key ENHANZE-enabled therapeutics. The adjusted EBITDA also saw a significant rise to $162 million, resulting in a 54% increase in net income to $118 million.
Another report by Baptista Research titled “Halozyme Therapeutics: European Market Expansion to Capture The Oncology Treatment Market!” praises the company’s robust financial and operational performance in 2024. Halozyme exceeded the $1 billion total revenue mark for the first time, marking a 22% increase over the previous year. Strong growth in royalty revenue, up 27% to $571 million, coupled with advancements in collaborative agreements, contributed to this achievement. The success of subcutaneous formulations of DARZALEX, Phesgo, and the introduction of VYVGART Hytrulo for generalized myasthenia gravis were key drivers of the company’s high-margin royalty revenue.
A look at Halozyme Therapeutics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Halozyme Therapeutics, Inc. shows a promising long-term outlook based on a combination of factors. With a high growth score of 4, the company is positioned well for future expansion and development. This indicates strong potential for advancing its products in the diabetes, cancer, dermatology, and drug delivery markets. Additionally, a resilience score of 3 suggests the company has the ability to withstand challenges and maintain stability in the face of uncertainties, which is essential for long-term success.
While Halozyme Therapeutics may not score as high in value and dividend factors, with scores of 2 and 1 respectively, its momentum score of 3 reflects positive upward movement and market interest. Overall, the company’s innovative platform technology, focused on recombinant human hyaluronidase plus additional enzymes, positions it well for future collaborations and growth opportunities in the biopharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
